MT. KISCO, N.Y., July 5, 2012 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD) a leading industry provider of all-natural products for immune system support from yeast beta-glucan, today announced the Company will prepare and file with the Securities and Exchange Commission ("SEC") a Registration Statement on Form 10, relating to the Company becoming a reporting company under Section 12(g) of the Securities Exchange Act of 1934, as amended.
Additional recent company milestones include:
-
PFK LLP, New York, completed audited Financials for years 2009, 2010, and 2011 (clean opinion)
-
recently presented clinical data at the World Immune response Meeting (WIRM) in Davos, Switzerland
-
new corporate website: www.immudyne.com
-
re-purchased and retired 3 million options
-
upgraded OTC markets (www.otcmarkets.com) status to Fully Current
- retired of 1,136,842 shares in Q3/Q4
Immudyne has approximately 29 million shares outstanding.
About Immudyne
Immudyne makes immune system support products:
-
all natural derived from yeast (notable the purest)
-
protected by numerous patents/proprietary trade secret know how
-
Clinical evidence
-
For pharmaceutical, nutraceutical, and topical/aesthetic dermatological
- best in class/stable and reliable
Immudyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com (currently being transformed). Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates,""believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.